• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Hospira`s Retacrit (darbepoetin alfa) Receives Suppl Approval in the U.S.

    FDA

    Pfizer`s Hospira pulls 5 lots of hospital injectable drugs

    FIERCE PHARMA

    Hospira Inc. Issues A Voluntary Nationwide Recall For Buprenorphine HCL

    FDA

    Hospira`s Biologic Nivestym (filgrastim-aafi) Receives Approval in the U.S.

    FDA

    Pfizer`s Hospira rings in new year with fresh round of recalls

    FIERCE PHARMA

    Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, 8.4% Sodium Bicarbonate Injection, and Atropine Sulfate Injection Due to the Potential Presence of Glass Particulate Matter

    FDA

    Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Bleomycin for Injection, USP 15 Units Single Dose ONCO-TAIN™ Glass Fliptop Vial Due To The Potential For Presence of Glass Particulate Matter

    FDA

    Enforcement Report - Week of November 15, 2023

    FDA

    Hospira, Inc. Issues a Voluntary Nationwide Recall for 4.2% Sodium Bicarbonate Injection, USP and 1% and 2% Lidocaine HCl Injection, USP Due to the Potential for Presence of Glass Particulate Matter

    FDA

    Enforcement Report - Week of February 1, 2023

    FDA

    Enforcement Report - Week of January 11, 2023

    FDA

    Appeals court sides with Pfizer in patent fight with Astellas

    FIERCE PHARMA

    Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Vancomycin Hydrochloride

    FDA

    Hospira`s Generic Regadenoson Receives Approval in the U.S.

    FDA

    Hospira Issues A Voluntary Nationwide Recall For One Lot of Propofol Injectable

    FDA

    Hospira, Inc. Generic Bortezomib Receives Approval in the U.S.

    FDA

    Hospira issues a recall for propofol due to visible particulate

    ENDPTS

    Hospira Issues a Voluntary Nationwide Recall for One Lot of Propofol Injectable Emulsion

    FDA

    Hospira`s Generic Pemetrexed Disodium Receives Approval in the U.S.

    FDA

    Delaware court rules against Gilead and Astellas in years-long patent case

    ENDPTS

    Eagle Reaches Settlement Agreement with Hospira Related to BENDEKA

    GLOBENEWSWIRE

    Hospira`s Generic Bortezomib Receives Approval in the U.S.

    FDA

    The Biosimilars Forum`s Julie Reed on What She`s Learned

    CENTERFORBIOSIMILARS

    Hospira, Inc`s Generic Aztreonam Receives Approval In US

    FDA

    Hospira, Inc’s Generics Aztreonam Receives Approvals In US

    FDA

    BioCina completes takeover of Pfizer-owned Australia plant; and more

    ENDPTS

    Enforcement Report - Week of September 22, 2021

    FDA

    Recall report: Amino acid IV pulled after foreign substances found in batch

    ENDPTS

    ICU Medical Issues a Voluntary Nationwide Recall of Aminosyn II 15%

    FDA

    FDA Issues Form 483 to Hospira Inc

    FDA

    Hospira Issues A Voluntary Nationwide Recall for One Lot of 0.5% Bupivacaine Hydrochloride Injection

    FDA

    Hospira`s Nivestym(Filgrastim-aafi)Receives Receives Supplemental Approval In US

    FDA

    FDA Issues Form 483 to Hospira

    FDA

    Hospira`s Nyvepria (pegfilgrastim) Receives Receives Supplemental Approval In US

    FDA

    FDA Issues Form 483 to Hospira Inc A Pfizer Company

    FDA

    FDA Issues Form 483 to Hospira Inc. A Pfizer Company

    FDA

    FDA Issues Form 483 to Hospira Inc.

    FDA

    FDA Issues Form 483 to Hospira Boulder, Inc.

    FDA

    Motion to Dismiss Denied in Amgen v. Hospira BPCIA

    BIGMOLECULEWATCH

    Pfizer’s Newest Vaccine Plant Has Persistent Mold Issues, History of Recalls

    KHN

    Hospira`s Pemetrexed Receives Tentative Approval in US

    FDA

    Par Pharmaceutical, Inc. v. Hospira, Inc. (Fed. Cir. 2020)

    PATENTDOCS

    Hospira`s Generic Epoetin Alfa Receives Supplemental Approval in US

    FDA

    Supreme Court Passes on Eli Lilly Patent Infringement Win

    BLOOMBERGLAW

    Hospira`s Nyvepria (Pegfilgrastim) Receives Supplemental Approval in US

    FDA

    Amgen Sues Pfizer and Hospira for Patent Infringement to Hospira’s Filgrastim

    BIGMOLECULEWATCH

    Epogen IP Fight Ends With Hospira Paying More Than $70M

    LAW360

    Pfizer Moves to Dismiss Amgen’s Suit Over Proposed Neulasta Biosimilar

    BIGMOLECULEWATCH

    Hospira, Inc., et al.; Withdrawal of Approval of 15 Abbreviated NDA

    AMAZONAS

    Amgen Sues Pfizer Over Proposed Neulasta Biosimilar

    BIGMOLECULEWATCH

    Hospira Asks Federal Circuit to Take Fresh Look at Safe Harbor Ruling

    BIG MOLECULE WATCH

    Amgen Inc. v. Hospira, Inc. (Fed. Cir. 2019)

    PATENTDOCS

    Company led drug alert Paclitaxel 6 mg/ml concentrate for solution for infusion

    GOV

    Glenmark`s Baddi Mfg unit receives GMP certificate from European regulator

    ECONOMIC TIMES

    Morton Grove`s Withdrawal of Approval of 21 Abbreviated New Drug Applications

    FEDERALREGISTER

    Hospira`s Generic Bortezomib Receives Approval in US

    FDA

    Pfizer scrambles to fill void after Teva stops making chemo drug

    FIERCE PHARMA

    Catalent expands; Hospira and Novartis issue recalls

    FIERCE PHARMA

    Hospira, Inc., Issues Recall for one lot of BACTERIOSTATIC WATER for Injection

    FDA

    Eli Lilly & Co. v. Hospira, Inc. (Fed. Cir. 2019)

    PATENTDOCS

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.